SOUTH SAN FRANCISCO, Calif., July 7, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, presented data for two of the company’s oncology product candidates, Alocrest(tm) (vinorelbine liposomes injection, OPTISOME(tm)) and Menadione Topical Lotion, at the European Society for Medical Oncology Conference taking place July 3-6, 2008 in Lugano, Switzerland (ECLU). Alocrest is Hana’s OPTISOME(tm) encapsulated formulation of vinorelbine tartrate intended for the treatment of certain solid tumor cancers and lymphomas. Menadione is a topical agent that Hana is currently evaluating in a Phase 1 clinical trial, for the treatment and/or prevention of Epidermal Growth Factor Receptor Inhibitor (EGFRI) associated skin toxicities.
